Lates News

On July 10, BeiGene announced that the European Commission (EC) has approved the combination of tislelizumab, gemcitabine, and cisplatin for the first-line treatment of adult patients with metastatic or recurrent nasopharyngeal carcinoma (NPC) who are not suitable for curative surgery or radiotherapy.